Last reviewed · How we verify
Lispro insulin U-100 — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Lispro insulin U-100 (Lispro insulin U-100) — AstraZeneca.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Lispro insulin U-100 TARGET | Lispro insulin U-100 | AstraZeneca | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Lispro insulin U-100 CI watch — RSS
- Lispro insulin U-100 CI watch — Atom
- Lispro insulin U-100 CI watch — JSON
- Lispro insulin U-100 alone — RSS
Cite this brief
Drug Landscape (2026). Lispro insulin U-100 — Competitive Intelligence Brief. https://druglandscape.com/ci/lispro-insulin-u-100. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing